在日本，R0切除术后死于非胃癌原因的患者人数正在增加，部分原因是人口老龄化。然而，目前很少有研究全面调查胃癌手术后其他死亡原因的临床病理风险。本研究旨在建立一个风险评分，以预测这种死亡。我们回顾了2010年1月至2014年12月期间在日本9家机构接受胃癌手术的3575名患者的临床数据。最终的研究人群为1758名患者，分配到 A 组（ n = 187）：在手术后5年内死于其他原因的患者和 B 组（ n = 1571）：手术后生存≥5年的患者。多元分析确定了九个特征作为导致生存不良的风险因素：年龄≥75岁，男性，体重指数<22 kg/m2，东合作组织肿瘤学绩效状态（≥1），糖尿病，心血管/脑血管疾病，其他恶性疾病，术前白蛋白水平<3.5 g/dL和全胃切除。将得分为0-2，3-4或5-9（每个特征得1分）的患者分为低风险，中风险和高风险组。低、中、高风险组的5年生存率分别为96.5％、85.3％和56.5％，高风险组的危险比（95％置信区间）为16.33（10.85-24.58，p <0.001）。本研究定义的风险评分可能对预测胃癌手术后其他死亡原因有所帮助。© 2022。作者（s）独家授权给国际胃癌协会和日本胃癌协会。

The number of patients who die from causes other than gastric cancer after R0 resection is increasing in Japan, due in part to the aging population. However, few studies have comprehensively investigated the clinicopathological risks associated with deaths from other causes after gastrectomy. This study aimed to build a risk score for predicting such deaths.We retrospectively reviewed clinical data for 3575 patients who underwent gastrectomy for gastric cancer at nine institutions in Japan between January 2010 and December 2014.The final study population of 1758 patients were assigned to Group A (n = 187): patients who died from other causes within 5 years of surgery, and Group B (n = 1571): patients who survived ≥ 5 years after surgery. Multivariate analysis identified nine characteristics as risk factors for poor survival: age ≥ 75 years, male sex, body mass index < 22 kg/m2, Eastern Cooperative Oncology Group Performance Status (≥ 1), diabetes mellitus, cardiovascular/cerebrovascular disease, other malignant diseases, preoperative albumin level < 3.5 g/dL, and total gastrectomy. Patients with risk scores of 0-2, 3-4, or 5-9 (based on 1 point per characteristics) were classified into Low-risk, Intermediate-risk, and High-risk groups, respectively. The 5-year survival rates were 96.5%, 85.3%, and 56.5%, for the Low-, Intermediate-, and High-risk groups, respectively, and the hazard ratio (95% confidence intervals) was 16.33 (10.85-24.58, p < 0.001) for the High-risk group.The risk score defined here may be useful for predicting deaths from other causes after curative gastrectomy.© 2022. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association.